Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alexza Pharmaceuticals

Request full access

Alexza Pharmaceuticals - Alexza Pharmaceuticals - Welcome

Mountain View, United StatesFounded 2001Biotech & Life Sciences

About Alexza Pharmaceuticals

Founded in 2000 by Alejandro Zaffaroni and Thomas B. King, Alexza Pharmaceuticals embarked on a mission to innovate drug delivery systems. The company focused on developing proprietary products for acute and intermittent conditions, utilizing their unique Staccato system. This technology allowed for rapid drug delivery through inhalation, offering a novel approach to treatment.

In March 2006, Alexza Pharmaceuticals made a significant leap by going public. The company staged its Initial Public Offering (IPO), pricing 5.5 million shares at $8 each. This move was pivotal, providing the necessary capital to advance their research and development efforts.

A decade later, in May 2016, Alexza Pharmaceuticals experienced another major milestone. The company was acquired by Grupo Ferrer Internacional for $55 million. This acquisition marked a new chapter, integrating Alexza's innovative technologies with Ferrer's global reach and resources.

Throughout its journey, Alexza Pharmaceuticals remained committed to transforming patient care through its cutting-edge inhalation therapies. The company's story is a testament to the impact of innovation in the pharmaceutical industry, highlighting the potential of novel drug delivery systems to improve treatment outcomes.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2001
Headquarters
Mountain View, United States
Listing
IPO 2006
Employees
84
Open positions
5
Dealroom signal
60.6/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Feb 2016 $5M — Undisclosed —
POST IPO EQUITYOther financing Mar 2014 $45M — Undisclosed —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026 $5M 0%
2025 $5M 0%
2024 $5M 0%
2023 $5M 0%
2022 $5M 0%
2021 $5M 0%
2020 $5M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Alexza Pharmaceuticals website traffic

Latest recorded traffic for Alexza Pharmaceuticals is 2.6K monthly website visits, up 100% over the last three months. Alexza Pharmaceuticals's team declined 25% over the past year.

Latest monthly visits2.6K 3-month web change+100% 1-year team growth-25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alexza Pharmaceuticals in the Mountain View ecosystem

Live from Dealroom

The Alexza Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later5 investors entered at this stage

  • Alloy Ventures
  • Delphi Ventures
  • 5AM Ventures
  • MDS Capital
  • Pacific Rim Ventures

Other known investors4 additional known investors

  • Stanford University
  • Abingworth
  • Hercules Capital
  • Lumira Ventures
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.1%
🇪🇸 Spain1.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alexza Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alexza Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.